Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel
Abstract Introduction For patients with psychosis, early, intensive therapeutic intervention is thought to improve long-term outcomes. Furthermore, patients with a first-episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit ov...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-01-01
|
| Series: | Neurology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40120-024-00700-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585325306707968 |
|---|---|
| author | Miquel Bernardo Marina Díaz Marsá Ana González-Pinto Manuel Martín Carrasco Víctor Pérez Sola Pilar Alejandra Sáiz Eduard Vieta Marta Torrens Celso Arango Benedicto Crespo-Facorro |
| author_facet | Miquel Bernardo Marina Díaz Marsá Ana González-Pinto Manuel Martín Carrasco Víctor Pérez Sola Pilar Alejandra Sáiz Eduard Vieta Marta Torrens Celso Arango Benedicto Crespo-Facorro |
| author_sort | Miquel Bernardo |
| collection | DOAJ |
| description | Abstract Introduction For patients with psychosis, early, intensive therapeutic intervention is thought to improve long-term outcomes. Furthermore, patients with a first-episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the longer term if they continue low-dose antipsychotic treatment. Lurasidone is an atypical antipsychotic agent which is approved in Europe for the treatment of schizophrenia in adults and adolescents (13–17 years). The efficacy and tolerability of lurasidone have been demonstrated in both antipsychotic-naïve and previously treated patients. Areas Covered This paper provides a review and commentary regarding the use of lurasidone in patients with FEP. Case studies based on the authors’ clinical experiences with lurasidone in real-world practice are provided. Expert Opinion In our experience, lurasidone has shown efficacy in FEP in different patient profiles, including those with psychoses associated with substance use disorders. Lurasidone provides clinically relevant benefits, especially in patients with affective symptomatology, and has a good tolerability profile. |
| format | Article |
| id | doaj-art-eedc7389eb05447b83fa76e33d769d49 |
| institution | Kabale University |
| issn | 2193-8253 2193-6536 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Neurology and Therapy |
| spelling | doaj-art-eedc7389eb05447b83fa76e33d769d492025-01-26T12:58:39ZengAdis, Springer HealthcareNeurology and Therapy2193-82532193-65362025-01-01141859810.1007/s40120-024-00700-yEfficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert PanelMiquel Bernardo0Marina Díaz Marsá1Ana González-Pinto2Manuel Martín Carrasco3Víctor Pérez Sola4Pilar Alejandra Sáiz5Eduard Vieta6Marta Torrens7Celso Arango8Benedicto Crespo-Facorro9Department of Psychiatry and Psychology, Clínic Barcelona, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAMHospital Clínico San Carlos, Universidad Complutense, CIBERSAMHospital Universitario de Álava, BIOARABA. UPV/EHU, CIBERSAMClínica Psiquiátrica Padre Menni, Pamplona, FIDMAG Research FoundationMental Health Institute Hospital del Mar, Barcelona, Hospital del Mar Research Institute, University Pompeu Fabra, University of Vic-Central Catalunya, RIAPADDepartment of Psychiatry, Universidad de Oviedo, CIBERSAM, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Neurociencias del Principado de Asturias (INEUROPA), Servicio de Salud del Principado de Asturias (SESPA)Department of Psychiatry and Psychology, Clínic Barcelona, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAMMental Health Institute Hospital del Mar, Barcelona, Hospital del Mar Research Institute, University Pompeu Fabra, University of Vic-Central Catalunya, RIAPADDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón School of Medicine, Universidad Complutense, IiSGM, CIBERSAMDepartment of Psychiatry, Faculty of Medicine, Mental Health Unit, Virgen del Rocio University Hospital, Translational Psychiatry Group, IBiS-CSIC, CIBERSAM, University of SevilleAbstract Introduction For patients with psychosis, early, intensive therapeutic intervention is thought to improve long-term outcomes. Furthermore, patients with a first-episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the longer term if they continue low-dose antipsychotic treatment. Lurasidone is an atypical antipsychotic agent which is approved in Europe for the treatment of schizophrenia in adults and adolescents (13–17 years). The efficacy and tolerability of lurasidone have been demonstrated in both antipsychotic-naïve and previously treated patients. Areas Covered This paper provides a review and commentary regarding the use of lurasidone in patients with FEP. Case studies based on the authors’ clinical experiences with lurasidone in real-world practice are provided. Expert Opinion In our experience, lurasidone has shown efficacy in FEP in different patient profiles, including those with psychoses associated with substance use disorders. Lurasidone provides clinically relevant benefits, especially in patients with affective symptomatology, and has a good tolerability profile.https://doi.org/10.1007/s40120-024-00700-yFirst-episode psychosisTreatmentAntipsychoticSchizophreniaTolerabilityLurasidone |
| spellingShingle | Miquel Bernardo Marina Díaz Marsá Ana González-Pinto Manuel Martín Carrasco Víctor Pérez Sola Pilar Alejandra Sáiz Eduard Vieta Marta Torrens Celso Arango Benedicto Crespo-Facorro Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel Neurology and Therapy First-episode psychosis Treatment Antipsychotic Schizophrenia Tolerability Lurasidone |
| title | Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel |
| title_full | Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel |
| title_fullStr | Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel |
| title_full_unstemmed | Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel |
| title_short | Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel |
| title_sort | efficacy of lurasidone in first episode psychosis patient phenotypes dosage and recommendations from an expert panel |
| topic | First-episode psychosis Treatment Antipsychotic Schizophrenia Tolerability Lurasidone |
| url | https://doi.org/10.1007/s40120-024-00700-y |
| work_keys_str_mv | AT miquelbernardo efficacyoflurasidoneinfirstepisodepsychosispatientphenotypesdosageandrecommendationsfromanexpertpanel AT marinadiazmarsa efficacyoflurasidoneinfirstepisodepsychosispatientphenotypesdosageandrecommendationsfromanexpertpanel AT anagonzalezpinto efficacyoflurasidoneinfirstepisodepsychosispatientphenotypesdosageandrecommendationsfromanexpertpanel AT manuelmartincarrasco efficacyoflurasidoneinfirstepisodepsychosispatientphenotypesdosageandrecommendationsfromanexpertpanel AT victorperezsola efficacyoflurasidoneinfirstepisodepsychosispatientphenotypesdosageandrecommendationsfromanexpertpanel AT pilaralejandrasaiz efficacyoflurasidoneinfirstepisodepsychosispatientphenotypesdosageandrecommendationsfromanexpertpanel AT eduardvieta efficacyoflurasidoneinfirstepisodepsychosispatientphenotypesdosageandrecommendationsfromanexpertpanel AT martatorrens efficacyoflurasidoneinfirstepisodepsychosispatientphenotypesdosageandrecommendationsfromanexpertpanel AT celsoarango efficacyoflurasidoneinfirstepisodepsychosispatientphenotypesdosageandrecommendationsfromanexpertpanel AT benedictocrespofacorro efficacyoflurasidoneinfirstepisodepsychosispatientphenotypesdosageandrecommendationsfromanexpertpanel |